GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Imagion Biosystems Ltd (ASX:IBX) » Definitions » EV-to-Revenue

Imagion Biosystems (ASX:IBX) EV-to-Revenue : 1.97 (As of Sep. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Imagion Biosystems EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Imagion Biosystems's enterprise value is A$3.70 Mil. Imagion Biosystems's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was A$1.88 Mil. Therefore, Imagion Biosystems's EV-to-Revenue for today is 1.97.

The historical rank and industry rank for Imagion Biosystems's EV-to-Revenue or its related term are showing as below:

ASX:IBX' s EV-to-Revenue Range Over the Past 10 Years
Min: -114.66   Med: 47.75   Max: 664.45
Current: 1.97

During the past 7 years, the highest EV-to-Revenue of Imagion Biosystems was 664.45. The lowest was -114.66. And the median was 47.75.

ASX:IBX's EV-to-Revenue is ranked better than
68.06% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.18 vs ASX:IBX: 1.97

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-09-25), Imagion Biosystems's stock price is A$0.026. Imagion Biosystems's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was A$0.06. Therefore, Imagion Biosystems's PS Ratio for today is 0.45.


Imagion Biosystems EV-to-Revenue Historical Data

The historical data trend for Imagion Biosystems's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imagion Biosystems EV-to-Revenue Chart

Imagion Biosystems Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial 24.96 641.86 308.43 57.23 12.73

Imagion Biosystems Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 57.23 - 12.73 -

Competitive Comparison of Imagion Biosystems's EV-to-Revenue

For the Diagnostics & Research subindustry, Imagion Biosystems's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imagion Biosystems's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's EV-to-Revenue falls into.



Imagion Biosystems EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Imagion Biosystems's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3.699/1.875
=1.97

Imagion Biosystems's current Enterprise Value is A$3.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was A$1.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Imagion Biosystems  (ASX:IBX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Imagion Biosystems's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.026/0.058
=0.45

Imagion Biosystems's share price for today is A$0.026.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was A$0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Imagion Biosystems EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Imagion Biosystems's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Imagion Biosystems Business Description

Traded in Other Exchanges
Address
5601 Oberlin Drive, Suite 100, San Diego, CA, USA, 92121
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

Imagion Biosystems Headlines

No Headlines